IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies. We are focused on the development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials.
IO Biotech has achieved a proven track record of progressing pre-clinical and clinical compounds:
- Two lead anti-cancer therapies targeting IDO and PD-L1 are in clinical development
- Several compounds finalizing the preclinical phase
IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board. IO Biotech is a privately held company with a solid financial position funded by experienced investors: Lundbeckfonden Emerge, Novo Seeds & Sunstone.
IO Biotech is located in Copenhagen, Denmark and was founded in December 2014 as a spin-out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic products.
IO Biotech has raised a total of EUR 159 million of capital. Most recently, in January 2021, IO Biotech completed a series B of EUR 127 M with the participation of Lundbeckfonden Emerge, Novo Seeds, Sunstone Life Science Ventures, HBM Partners, Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital.